Exciting Progress with VT3989 in Mesothelioma Treatment
Vivace Therapeutics, a pioneering company focused on developing innovative cancer therapies, has unveiled promising data regarding their latest treatment candidate, VT3989. This first-in-class therapy targets the Hippo pathway, a crucial regulator in cell growth and survival, making it a significant addition to the fight against cancer.
Recent Study Findings
The latest data from a Phase I/II clinical trial demonstrated VT3989's remarkable efficacy in refractory mesothelioma patients. In this study, conducted with a cohort of 22 participants, the findings revealed an overall response rate (ORR) of 32%, meaning that 7 out of 22 patients experienced a partial response to the treatment. Additionally, an impressive disease control rate (DCR) of 86% was achieved, indicating that the majority of patients either responded positively or maintained stable disease.
Safety and Side Effects
The safety profile of VT3989 appears to be well managed, with no dose-limiting toxicities reported in 172 patients undergoing treatment. Most side effects were classified as mild to moderate, contributing to a low discontinuation rate of merely 3.5%. The most common treatment-related side effects included manageable fatigue, reversible increases in proteinuria, and mild swelling.
Future Clinical Trials
Building on these favorable results, Vivace is set to advance VT3989 into a Phase 3 registrational trial dedicated to mesothelioma patients in the near future. Lead investigator, Timothy A. Yap, expressed optimism regarding the therapy's potential, emphasizing the significant disease control achieved, especially in patients who have already undergone various treatments.
Clinical Implications and Significance
Mesothelioma, a challenging cancer to treat, often leaves patients with limited options after first-line therapies. The encouraging data from this study positions VT3989 as a vital candidate for providing new hope to those battling this aggressive disease.
Regulatory Designations
VT3989 has gained recognition from the United States Food and Drug Administration, receiving both Orphan Drug Designation and Fast Track Designation. These approvals are instrumental as they pave the way for the expedited development of this innovative therapy, particularly for patients with unresectable malignant mesothelioma who have seen disease progression post-standard therapies.
About Vivace Therapeutics
Vivace Therapeutics is dedicated to developing first-in-class small molecule therapies aimed at targeting the Hippo pathway, with a goal of addressing high unmet medical needs in oncology. The company's innovative approach and commitment to research have enabled it to raise significant capital to further its mission, having accumulated $105 million to date.
Contact Information for Inquiries
For more information regarding VT3989 and its clinical development, you can contact Sofie Qiao, Ph.D., President and CEO of Vivace Therapeutics, at 650-666-2753. For media inquiries, reach out to Tim Brons at Vida Strategic Partners at 646-319-8981.
Frequently Asked Questions
What is VT3989?
VT3989 is a first-in-class therapy that targets the Hippo pathway, showing significant antitumor activity in refractory mesothelioma patients.
What were the key findings from the recent study?
The study revealed a 32% overall response rate and an 86% disease control rate among participants, with manageable safety profiles.
When will VT3989 enter Phase 3 trials?
The Phase 3 registrational trial for VT3989 in mesothelioma patients is anticipated to begin in the first half of 2026.
What regulatory recognitions has VT3989 received?
VT3989 has obtained Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of mesothelioma.
Who can I contact for more information?
For inquiries about VT3989, contact Sofie Qiao, CEO, at 650-666-2753 or Tim Brons for media inquiries at 646-319-8981.
